Dianthus Therapeutics (NASDAQ:DNTH) Earns Buy Rating from Guggenheim

Dianthus Therapeutics (NASDAQ:DNTH)‘s stock had its “buy” rating reiterated by investment analysts at Guggenheim in a research report issued on Wednesday,Benzinga reports. They currently have a $84.00 price target on the stock. Guggenheim’s price target suggests a potential upside of 264.41% from the stock’s previous close.

A number of other equities analysts also recently commented on DNTH. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a report on Wednesday. TD Cowen initiated coverage on shares of Dianthus Therapeutics in a research note on Friday, December 20th. They set a “buy” rating for the company. Finally, Raymond James upgraded shares of Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $52.14.

Dianthus Therapeutics Price Performance

Shares of NASDAQ:DNTH traded down $0.33 during trading hours on Wednesday, hitting $23.05. The company’s stock had a trading volume of 21,600 shares, compared to its average volume of 243,796. The firm’s fifty day moving average price is $22.65 and its 200 day moving average price is $24.97. Dianthus Therapeutics has a 52 week low of $18.13 and a 52 week high of $33.77. The company has a market capitalization of $682.24 million, a price-to-earnings ratio of -9.23 and a beta of 1.82.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04. The company had revenue of $1.33 million during the quarter, compared to analyst estimates of $1.40 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. On average, equities research analysts predict that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. R Squared Ltd purchased a new stake in Dianthus Therapeutics in the fourth quarter valued at approximately $26,000. Quest Partners LLC raised its position in Dianthus Therapeutics by 112,400.0% during the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock worth $31,000 after buying an additional 1,124 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in Dianthus Therapeutics during the 4th quarter valued at approximately $33,000. KBC Group NV purchased a new stake in shares of Dianthus Therapeutics in the 4th quarter valued at $35,000. Finally, BNP Paribas Financial Markets acquired a new stake in shares of Dianthus Therapeutics in the fourth quarter worth $59,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.